Fund moves
997KShares reported
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
TMO · NYSE · Life Sciences Tools & Services
Thermo Fisher Scientific (TMO) · oqro.io/stocks/TMO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$688.75−3.99 (−0.58%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Thermo Fisher Scientific was filed in the last 90 days. The latest on record was on Feb 21, 2025.
Since 2006, Thermo Fisher Scientific insiders reported 16 open-market purchases and 2,917 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2024.
In the last 90 days, 3 insiders of Thermo Fisher Scientific (TMO) reported 23 open-market sales worth $20.2M in total on SEC Form 4. The largest seller by value was Marc N Casper, with $12.7M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 11 trades in Thermo Fisher Scientific (TMO) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Michael A. Rulli (OH06), Sen. Alan Armstrong, Rep. Dan Newhouse (WA04) and 3 other members.
Thermo Fisher Scientific's next results are expected on Jan 27, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+20.0% (+$114.96) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $573.79 on Nov 19, 2025 to $688.75 on Nov 19, 2026 (+20.0%). Disclosed in this range: 8 insider trades, 132 pre-arranged insider sales, 3 Congress trades, and 418 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Life Sciences Tools & Services company based in Waltham, Massachusetts.
Last 12 months
+20.0%
Market value
$255B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.78M shares sold short (1.3% of shares outstanding), −2.1% vs the previous count, 2.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$12.1B
+9.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$7.6B
This quarter $2.11B, a year earlier $1.83B
Net debt
$35.6B
Debt $41.1B, cash $5.46B, at Sep 26, 2026
Backlog
$29.9B
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 21, 2026.
Revenue, fiscal 2025
$44.6B
+3.9% vs the year before
Net income, fiscal 2025
$6.7B
As reported in the annual filing
Shares outstanding
371M
As of Sep 26, 2026
In fiscal 2025 the company spent $3B buying back its own shares and $636M on dividends. Cash actually paid, from its cash-flow statement.
Next ex-dividend date Dec 15, 2026: $0.47 a share (quarterly), payable Jan 15, 2027. Calendar
New federal contracts from the last 12 months add up to 0.06% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Thermo Fisher Scientific over the 12 months to Nov 20, 2026: 4 FDA records, 4 executive contributions and 1 WARN notice.
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeAgainst the S&P 500 over the year
Since Nov 18, 2025, TMO is up 19.6% and the index fund is up 8.5%: 11 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much TMO moves
Beta 0.7 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Vanguard Capital Management
13G · passive · Crossed 5% · 28M shares · filed Apr 30, 2026
FMR LLC
13G · passive · Crossed 5% · 22.3M shares · filed Nov 5, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Thermo Fisher Scientific reported 16 open-market purchases and 2,917 sales since 2006; purchases in 8 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $74.8M132×132 trades |
| 2025 | — | $136M89×89 trades |
| 2024 | $11K2×2 trades | $201M222×222 trades |
| 2023 | $2.1K1×1 trade | $105M143×143 trades |
| 2022 | — | $146M241×241 trades |
| 2021 | — | $132M94×94 trades |
| 2020 | — | $212M93×93 trades |
| 2019 | — | $53.5M34×34 trades |
| 2018 | — | $104M37×37 trades |
| 2017 | — | $42.1M25×25 trades |
| 2016 | — | $72.8M55×55 trades |
| 2015 | $134K1×1 trade | $75.2M48×48 trades |
| 2014 | — | $77.7M36×36 trades |
| 2013 | — | $41.6M17×17 trades |
| 2012 | — | $62.9M36×36 trades |
| 2011 | — | $19.8M18×18 trades |
| 2010 | $327K4×4 trades | $13.5M23×23 trades |
| 2009 | $47K2×2 trades | $4.53M19×19 trades |
| 2008 | $75K3×3 trades | $51.1M200×200 trades |
| 2007 | $54K1×1 trade | $235M1115×1,115 trades |
| 2006 | $104K2×2 trades | $107M240×240 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records
3 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
People read Thermo Fisher Scientific's Wikipedia article about 350 times a day over the last week, close to the 400 on a usual day of the three months before.
May 14, 2026Busiest day: 1,400 views on Jul 8, 2026Nov 19, 2026
Views of the article Thermo Fisher Scientific, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
4 notices filed with state agencies, covering 317 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
65 certified in FY2026 Q3, vs 73 a year earlier. 65 positions in total, median offered wage $121K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 20, 2025. Read the filing
All 27 risk factor headings match the year before, give or take wording.
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 5 to our Consolidated Financial Statements – “Commitments and Contingencies”.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+3.6% on the year before ($23.2B). Operating income $3.35B, a 14% margin
+7.7% on the year before ($9.63B). Operating income $3.77B, a 36% margin
+1.2% on the year before ($7.46B). Operating income $1.74B, a 23% margin
+3.6% on the year before ($4.51B). Operating income $1.26B, a 27% margin
The segments reach the total once −$2.03B of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
+6.1% on the year before ($17.6B)
+4.2% on the year before ($17.8B)
−1.9% on the year before ($7.45B)
The company also reports Product revenues ($26B), which group lines above and are not added again.
+2.4% on the year before ($22.5B)
+8.9% on the year before ($10.9B)
+1.8% on the year before ($7.96B)
+2.3% on the year before ($1.56B)
The company also reports Other ($22.3B), United States ($22.2B), which group lines above and are not added again.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 11): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 7 more headings in the filing.
Short sale volume: 45.0% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 43.6%. FINRA daily files, to Nov 19, 2026.
Fails to deliver: 9,407 shares (about $6.53M) were not delivered on time for settlement on Oct 22, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 47.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (33.0% on ATS, 14.2% with other brokers), above its 26-week average of 45.1%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (12.0%), INTELLIGENT CROSS LLC (11.0%), SIGMA X2 (10.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last results
Oct 21, 2026
Within the 30 days after it, until Nov 20, 2026
Next results, expected
Jan 27, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Thermo Fisher Scientific's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Thermo Fisher Scientific's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.